17.48

0.23% 0.04

Seres Therapeutics Inc (MCRB)

Overview News Price History Option Chain Financials Discussions Forecast

Seres Therapeutics Inc stock is traded at $17.48, with a volume of 79,869. It is up +0.23% in the last 24 hours and up +27.13% over the past month. Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Previous Close:

$17.44

Open:

$17.5

24h Volume:

79,869

Relative Volume:

0.36

Market Cap:

$158.13M

Revenue:

$123.24M

Net Income/Loss:

$136.00K

P/E Ratio:

-874.00

EPS:

-0.02

Net Cash Flow:

$-148.99M

1W Performance:

+3.62%

1M Performance:

+27.13%

6M Performance:

+145.16%

1Y Performance:

+6.72%

1-Day Range:

$16.80

$17.90

1-Week Range:

$16.61

$18.86

52-Week Range:

$6.53

$29.98

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name

Seres Therapeutics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

617 945 9626

Address

200 SIDNEY STREET, CAMBRIDGE, MA

Employee

103

Twitter

@SeresTX

Next Earnings Date

2024-10-31

Latest SEC Filings

MCRB's Discussions on Twitter

Compare MCRB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MCRB Seres Therapeutics Inc	17.48	157.77M	123.24M	136.00K	-148.99M	-0.02
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-08-25	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-24-24	Downgrade	JP Morgan	Neutral → Underweight
Jun-26-23	Resumed	Oppenheimer	Outperform
Apr-21-23	Initiated	JP Morgan	Neutral
Jul-23-21	Downgrade	Goldman	Neutral → Sell
May-18-21	Resumed	Goldman	Neutral
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Aug-11-20	Upgrade	Jefferies	Hold → Buy
Apr-30-19	Initiated	Jefferies	Hold
Oct-22-18	Initiated	Chardan Capital Markets	Buy
Oct-13-17	Initiated	Oppenheimer	Outperform
Aug-04-17	Reiterated	H.C. Wainwright	Buy
Feb-01-17	Reiterated	FBR & Co.	Outperform
Aug-12-16	Reiterated	FBR Capital	Outperform
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Aug-01-16	Reiterated	H.C. Wainwright	Buy
Jul-29-16	Resumed	H.C. Wainwright	Buy
Mar-30-16	Initiated	FBR Capital	Outperform
Mar-03-16	Initiated	Guggenheim	Buy
Jan-25-16	Initiated	H.C. Wainwright	Buy
Oct-22-15	Upgrade	BofA/Merrill	Neutral → Buy
Jul-22-15	Initiated	Canaccord Genuity	Buy
Jul-21-15	Initiated	Goldman	Neutral
Jul-21-15	Initiated	Leerink Partners	Outperform

View All

Seres Therapeutics Inc Stock (MCRB) Latest News

04:17 AM

Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat

04:17 AM

Dec 03, 2025

Will Seres Therapeutics Inc. (1S90) stock outperform foreign stocksWeekly Risk Summary & Real-Time Chart Pattern Alerts - Newser

Dec 03, 2025

Will Seres Therapeutics Inc. (1S90) stock beat value stocks2025 Year in Review & Verified Chart Pattern Signals - Newser

Dec 03, 2025

Dec 02, 2025

What market sentiment indicators show for Seres Therapeutics Inc. (1S90) stock2025 Institutional Moves & Free Daily Entry Point Trade Alerts - Newser

Dec 02, 2025

What risks investors should watch in Seres Therapeutics Inc. stock2025 Volatility Report & AI Driven Stock Movement Reports - Newser

Dec 02, 2025

Is Seres Therapeutics Inc. stock dividend yield sustainablePortfolio Update Report & Growth Oriented Trade Recommendations - Newser

Dec 02, 2025

Is Seres Therapeutics Inc. stock positioned for long term growth2025 Support & Resistance & Growth Focused Stock Pick Reports - Newser

Dec 02, 2025

Dec 01, 2025

Seres Therapeutics (MCRB) Stock Analysis Report | Financials & Insights - Benzinga

Dec 01, 2025

Nov 28, 2025

Volatility Watch: Why Seres Therapeutics Inc. stock is rated strong buyJuly 2025 Review & High Accuracy Trade Alerts - moha.gov.vn

Nov 28, 2025

Nov 27, 2025

A look into Seres Therapeutics Inc (MCRB)’s deeper side - Setenews

Nov 27, 2025

Why Seres Therapeutics Inc. stock is rated strong buyMarket Performance Report & Fast Exit Strategy with Risk Control - BỘ NỘI VỤ

Nov 27, 2025

Is Seres Therapeutics Inc. stock affected by interest rate hikesTrade Entry Summary & Target Return Focused Picks - BỘ NỘI VỤ

Nov 27, 2025

Nov 24, 2025

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - The Manila Times

Nov 24, 2025

Seres Therapeutics (Nasdaq: MCRB) to join Piper Sandler 37th Annual Healthcare Conference - Stock Titan

Nov 24, 2025

Nov 22, 2025

Seres Therapeutics Inc Stock Analysis and ForecastHead and Shoulders Patterns & Big Gains Low Cost - earlytimes.in

Nov 22, 2025

Nov 21, 2025

What analysts say about Seres Therapeutics Inc stockMACD Histogram Signals & Budget Friendly Capital Growth - earlytimes.in

Nov 21, 2025

Should You Watch Rane Engine Valve Limited for Sector Rotation UpsideWeekly Market Snapshot & Free Stock Market Mentorship Programs - earlytimes.in

Nov 21, 2025

Can Poonawalla Fincorp Limited Deliver Consistent Free Cash FlowsMarket Depth Overview & Swing Trade Smarter With Data Insights - earlytimes.in

Nov 21, 2025